How many drugs treat Iridocyclitis?

Drug Landscape tracks 10 marketed treatments for Iridocyclitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/iridocyclitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Iridocyclitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Iridocyclitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Iridocyclitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	Corticosteroid	Glucocorticoid receptor	1998-01-01
Flarex	FLUOROMETHOLONE ACETATE	Harrow Health	Corticosteroid	Glucocorticoid receptor	1986-01-01
Fml	FLUOROMETHOLONE	AbbVie	Corticosteroid	Glucocorticoid receptor	1972-01-01
Medrifar	MEDRYSONE	AbbVie	Corticosteroid	Glucocorticoid receptor	1969-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Klaron	SULFACETAMIDE	Merck & Co.	Sulfonamide Antibacterial	Dihydrofolate reductase	1945-01-01
Lotemax	Lotemax	Tufts Medical Center		Glucocorticoid receptor
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

AbbVie · 2 drugs in Iridocyclitis
Bausch Health · 1 drug in Iridocyclitis
Generic (originally Merck) · 1 drug in Iridocyclitis
Generic (originally Merck/Upjohn) · 1 drug in Iridocyclitis
Generic (originally Schering) · 1 drug in Iridocyclitis
Hannover Medical School · 1 drug in Iridocyclitis
Harrow Health · 1 drug in Iridocyclitis
Merck & Co. · 1 drug in Iridocyclitis
Tufts Medical Center · 1 drug in Iridocyclitis
University Hospital, Angers · 1 drug in Iridocyclitis
· 1 drug in Iridocyclitis
University of Zurich · 1 drug in Iridocyclitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Iridocyclitis:

Cite this brief

Drug Landscape (2026). Iridocyclitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/iridocyclitis. Accessed 2026-06-10.

Iridocyclitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing